Rewiring of the pluripotency enhancer network during early mammalian development

早期哺乳动物发育过程中多能性增强子网络的重新布线

基本信息

项目摘要

PROJECT ABSTRACT: Pluripotency is the remarkable ability of a single cell to give rise to every cell type of the mammalian body plan. Pluripotent cells exist in epiblast of early implantation embryos. There are two well-described pluripotent cell types, those of the early versus late epiblast that can be modeled in vitro as naïve embryonic stem cells versus primed epiblast cells respectively. These cells differ minimally in terms of their expression profiles, yet vastly in terms of their epigenomes. In particularly, largely distinct enhancers drive expression of the same genes in the two states. The reason for the extensive enhancer rewiring in the absence of gene expression changes is unknown, but appears to be a critical aspect of early mammalian development. Preliminary results begin to address this problem by following the function of a single transcription factor Grhl2. Grhl2 is upregulated during embryonic stem to epiblast cell transition and is able to induce previously latent enhancers to a fully active state driving expression of proximal genes. Yet, these genes do not change expression during the transition. Evaluation of potential enhancers regulating the same genes in the embryonic stem cells uncovered the Klf2/4/5- related transcription factors as likely regulators of the genes in the naïve state. Indeed Grhl2 is upregulated just as Klf2/4/5 is downregulated. However, Klf2/4/5 regulates a much larger network of genes in the naive state than Grhl2 does in the primed state. Therefore, it appears that Grhl2 assumes control of a subset of Klf2/4/5 targets during the transition and that other transcription factors must assume control of other parts of the very large Klf2/4/5 network. These findings led to the hypothesis that during the early to late epiblast transition, large naïve regulatory networks are broken down into much smaller primed regulatory networks, providing the late epiblast cells the flexibility to differentiate down the divergent somatic lineages that form at gastrulation, immediately following the late epiblast stage. Then each of the smaller networks can be selectively maintained among the different lineages. Indeed, the Grhl2 network is excluded from the primitive streak while remaining expressed in the surrounding epiblast cells. To test the hypothesis, there are three specific aims. In aim 1, cutting edge technologies are used to identify all Klf2/4/5 and Grhl2 driven enhancer promoter interactions in the embryonic stem and epiblast cell states respectively in order to directly determine whether Grhl2 results in the rewiring of enhancer-promoter interactions among a subset of Klf2/4/5 targets. In aim 2, bioinformatics and novel biochemical methods are used to uncover additional epiblast cell transcription factors that rewire other subsets of the Klf2/4/5 driven network. In aim 3, single cell sequencing of wild-type and knockout embryos is used to explore the biological role for enhancer rewiring in vivo. Successful completion of this project will be highly significant as it will uncover novel paradigms of gene control that regulate cell fate and a cell’s unique development potential.
项目摘要: 多能性是单个细胞产生哺乳动物身体计划的每种细胞类型的显着能力。 早期植入胚胎的外胚层存在多能性细胞。有两种被充分描述的多能细胞 类型,早期与晚期外胚层,可以在体外模拟为幼稚胚胎干细胞与 致敏的上胚层细胞。这些细胞在表达谱方面差异很小,但在表达谱方面差异很大。 他们的表观基因组。特别地,在很大程度上不同的增强子驱动相同基因在细胞中的表达。 两个州。在没有基因表达变化的情况下,广泛的增强子重新布线的原因是 未知,但似乎是早期哺乳动物发育的一个关键方面。初步结果开始, 通过跟踪单个转录因子Grhl 2的功能来解决这个问题。Grhl 2在生长过程中上调, 胚胎干细胞向上胚层细胞的转变,并能够诱导先前潜伏的增强子完全激活 状态驱动近端基因的表达。然而,这些基因在过渡期间不会改变表达。 对调节胚胎干细胞中相同基因的潜在增强子的评估揭示了 Klf 2/4/5相关转录因子作为幼稚状态基因的可能调节因子。其实Grhl 2是 Klf 2/4/5下调。然而,Klf 2/4/5调节了一个更大的基因网络, 比Grhl 2在启动状态下的反应要快。因此,Grhl 2似乎控制了一个 在过渡期间,Klf 2/4/5靶点的亚群被抑制,并且其他转录因子必须承担对其他转录因子的控制。 Klf 2/4/5网络的一部分。这些发现导致了一种假设,即在早期到晚期, 上胚层过渡,大的幼稚调节网络被分解成小得多的启动调节网络, 网络,为晚期上胚层细胞提供了分化分化不同体细胞谱系的灵活性, 在原肠胚形成时形成,紧接着上胚层晚期。然后每个较小的网络可以 在不同的血统中选择性地维持。事实上,Grhl 2网络被排除在原始网络之外。 条纹,同时在周围的上胚层细胞中保持表达。为了验证这个假设,有三个 具体目标。在目标1中,使用尖端技术来识别所有Klf 2/4/5和Grhl 2驱动的增强子 分别在胚胎干细胞和上胚层细胞状态中的启动子相互作用,以直接确定 Grhl 2是否导致Klf 2/4/5靶标亚组中增强子-启动子相互作用的重新连接。在 目的2:利用生物信息学和新的生物化学方法来揭示额外的上胚层细胞转录 重新连接Klf 2/4/5驱动网络的其他子集的因素。在aim 3中,野生型的单细胞测序 和敲除胚胎用于探索增强子体内重新布线的生物学作用。成功 该项目的完成将具有非常重要的意义,因为它将揭示基因控制的新范例, 调节细胞命运和细胞独特的发育潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Blelloch其他文献

Robert Blelloch的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Blelloch', 18)}}的其他基金

Establishing the development basis for the morphological and functional asymmetry of the human chorion
建立人类绒毛膜形态和功能不对称的发育基础
  • 批准号:
    10673397
  • 财政年份:
    2023
  • 资助金额:
    $ 41.49万
  • 项目类别:
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
外泌体驱动的癌症进展免疫调节机制
  • 批准号:
    10381379
  • 财政年份:
    2021
  • 资助金额:
    $ 41.49万
  • 项目类别:
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
外泌体驱动的癌症进展免疫调节机制
  • 批准号:
    10671960
  • 财政年份:
    2019
  • 资助金额:
    $ 41.49万
  • 项目类别:
Iteratively redefining developmental potential through poised enhancers
通过稳定的增强剂迭代地重新定义发展潜力
  • 批准号:
    9753014
  • 财政年份:
    2017
  • 资助金额:
    $ 41.49万
  • 项目类别:
Rewiring of the pluripotency enhancer network during early mammalian development
早期哺乳动物发育过程中多能性增强子网络的重新布线
  • 批准号:
    9403957
  • 财政年份:
    2017
  • 资助金额:
    $ 41.49万
  • 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
  • 批准号:
    8582076
  • 财政年份:
    2013
  • 资助金额:
    $ 41.49万
  • 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
  • 批准号:
    8923178
  • 财政年份:
    2013
  • 资助金额:
    $ 41.49万
  • 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
  • 批准号:
    9122348
  • 财政年份:
    2013
  • 资助金额:
    $ 41.49万
  • 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
  • 批准号:
    8713966
  • 财政年份:
    2013
  • 资助金额:
    $ 41.49万
  • 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
  • 批准号:
    9519087
  • 财政年份:
    2013
  • 资助金额:
    $ 41.49万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.49万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了